U.S. Meibomian Gland Dysfunction Market, By Drug Type (Cyclosporine, Omega-3 supplements, Antibacterial eye drops, Steroids, AZR MD 001, TP 03, NOV03 (Novatears), HY02 - Minocycline), By Route of Administration (Oral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Published In : Aug 2023

Code : CMI4186

Pages :132

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

U.S. Meibomian Gland Dysfunction Market: Key Developments

In July 2020, The Ambu, a company that develops, produces, and markets diagnostic and life-supporting devices for hospitals and rescue services in North America, announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Scope ophthalmic.
In October 2022, Aldeyra Therapeutics, Inc. discovers and develops innovative therapies designed to treat immune-mediated diseases, completed the phase 3 clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for treating allergic conjunctivitis. The company presented the clinical data from the trial at the American Academy of Optometry 2022 Annual Meeting.
In April 2021, Hill-Rom Holdings Inc (Hillrom), a medical technology company that offers patient support systems, surgical solutions, and front-line care products, company introduced the Welch Allyn PanOptic Plus Ophthalmoscope devices that boast a 20X larger viewing area. Welch Allyn PanOptic Plus Ophthalmoscope and Welch Allyn MacroView Plus Otoscope Give Caregivers Better, Bolder, Brighter Views to Help Support Earlier Diagnosis and Treatment
In January 2022, Wassenburg Medical B.V., a company that provides endoscope reprocessing products and solutions in the U.S., announced that it had acquired Custom Ultrasonics, a U.S.-based medical equipment manufacturer. This acquisition will create additional growth in the U.S. market for both companies.
in January 2021, Kala Pharmaceuticals Inc. launched EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is now available in national and regional United States pharmaceutical distribution centers. Patients with a prescription can access EYSUVIS through their local retail pharmacies or home delivery.
in January 2022, Sun Pharma Canada Inc, a subsidiary of the India-based company Sun Pharmaceutical Industries Limited launched Cequa (cyclosporine ophthalmic solution 0.09 percent w/v), a calcineurin inhibitor immunomodulator. All these novel product launches may give the country a cutting edge in the market.